NCT01825603View on ClinicalTrials.gov

ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 9, 2013

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions
Ampulla of Vater AdenocarcinomaGallbladder AdenocarcinomaMetastatic Pancreatic AdenocarcinomaPancreatic AdenocarcinomaStage III Ampulla of Vater CancerStage III Intrahepatic CholangiocarcinomaStage III Pancreatic CancerStage IIIA Gallbladder CancerStage IIIA Hilar CholangiocarcinomaStage IIIB Gallbladder CancerStage IIIB Hilar CholangiocarcinomaStage IV Ampulla of Vater CancerStage IVA Gallbladder CancerStage IVA Hilar CholangiocarcinomaStage IVA Intrahepatic CholangiocarcinomaStage IVA Pancreatic CancerStage IVB Gallbladder CancerStage IVB Hilar CholangiocarcinomaStage IVB Intrahepatic CholangiocarcinomaStage IVB Pancreatic Cancer
Interventions
DRUG

ADH-1

Given IV

DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
collaborator

Adherex Technologies, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT01825603 - ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | Biotech Hunter | Biotech Hunter